SIRS
37
1
1
23
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.4%
2 terminated out of 37 trials
92.0%
+5.5% vs benchmark
8%
3 trials in Phase 3/4
9%
2 of 23 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 23 completed trials
Clinical Trials (37)
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock
CD64 and Antibiotics in Human Sepsis
Effects of Electrical Stimulation for Preventing Loss of Muscle Mass in Patients With SIRS, Sepsis and Septic Shock
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Efficacy of Intravenous In-line Filter in Patient Undergoing Cardiac Surgery
Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia
A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
mSEP: Testing of Physiological and Immune-metabolic Blood Markers for Maternal Sepsis
Performance Evaluation of the Nanomix eLab® CRP, PCT, and LAC Assays With the Nanomix eLab System
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Cytokine Hemoadsorption in ECMO Patients
SIRS in Cyanotic and Acyanotic Children in Cardiac Surgery
Early Detection of Glycocalyx Damage in Emergency Room Patients
Validation of Molecular and Protein Biomarkers in Sepsis
Early Identification of Sepsis in Children
Evaluation of CDSS in Detection of SIRS and Sepsis in Pediatric Patients
Utility of Presepsin in Distinguishing Between Sepsis and SIRS
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA